|
|
 | | | |
- close
- close
- close
- close
QUOTE AND NEWS
Marketwire
Mar 30
Comment
SAN FRANCISCO, CA -- (Marketwire) -- 03/30/12 -- Medivation, Inc. (NASDAQ: MDVN) today announced that the company will present data on enzalutamide (formerly MDV3100) at the American Association for Cancer Research (AACR) Annual Meeting in Chicago,
StreetInsider.com
Mar 16
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Management+Changes/Avanir+%28AVNR%29+Taps+Medivation%27s+%28MDVN%29+Palekar+as+CCO/7275181.html for the full story.
Benzinga
Mar 14
Comment
Medivation, Inc. (NASDAQ: MDVN) yesterday announced the pricing of its offering of $225 million aggregate principal amount of 2.625% convertible senior notes due April 1, 2017 registered under the Securities Act of 1933, as amended. Medivation...
TheStreet.com
Mar 8
Comment
Second update with new information on the Zytiga study plus other background.
RARITAN, N.J. (TheStreet) --Johnson & Johnson's prostate cancer drug Zytiga prolonged the lives of patients with less advanced disease, according to results of a...
FierceBiotech
Mar 5
Comment
Now that San Diego-based Aragon Pharmaceuticals has wrapped its early-stage work on their anti-androgen prostate cancer drug ARN-509 with some encouraging indications of its impact on tumors, the biotech has married up with a nontraditional...
Marketwire
Mar 2
Comment
SAN FRANCISCO, CA -- (Marketwire) -- 03/02/12 -- Medivation, Inc. (NASDAQ: MDVN) today announced that it will present at the following conferences in March: Patrick Machado, chief business and financial officer, will present at Cowen and Company's
Marketwire
Feb 29
Comment
SAN FRANCISCO, CA -- (Marketwire) -- 02/29/12 -- Medivation, Inc. (NASDAQ: MDVN) today provided a corporate update and reported its financial results for the fourth quarter and the year ended December 31, 2011. "With positive results in hand from our
FiercePharma
Feb 27
Comment
Medivation ($MDVN), which is developing a new treatment for prostate cancer, said a European survey found that doctors see a need for new treatments that extend patients' lives, with 85% of oncologists and 74% of urologists calling overall...
Benzinga
Feb 21
Comment
Shares of Medivation (NASDAQ: MDVN) are lower on the session by 4.24%, currently trading at $63.25. The stock has been moving largely higher over the past three months and is currently trading above the 50-day moving average.
Options traders...
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
